Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
Download as PDF May 07, 2024
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET
SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2024 financial results after the U.S. financial markets close on Monday, May 13, 2024. Journey Medical management will conduct a conference call and audio webcast on Monday, May 13, 2024 at 4:30 p.m. ET.
To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10188768/fc6df642e0. Please note that registered participants will receive their dial-in number upon registration.
A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical's website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical") is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology's most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical's common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission ("SEC"). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
Source: Journey Medical Corporation
Released May 7, 2024
Journey Medical Corporation将于2024年5月13日公布2024年第一季度财务业绩
以 PDF 格式下载 2024年5月7日
公司将于美国东部时间2024年5月13日下午 4:30 举办电话会议，讨论财务业绩并提供公司最新情况
亚利桑那州斯科茨代尔，2024年5月7日（GLOBE NEWSWIRE）——专注于销售和营销经美国食品药品管理局批准的用于治疗皮肤病的处方药产品的商业阶段制药公司Journey Medical（“Journey Medical” 或 “公司”）（纳斯达克股票代码：DERM）今天宣布，该公司将在2024年5月13日星期一美国金融市场收盘后发布其2024年第一季度财务业绩。Journey Medical管理层将于美国东部时间2024年5月13日星期一下午4点30分进行电话会议和网络音频直播。
要收听电话会议，美国境内的有关各方应拨打1-866-777-2509（国内）或1-412-317-5413（国际）。所有来电者应在预定开始时间前大约 10 分钟拨入，并要求参加 Journey Medical 电话会议。参与者可以通过导航到以下地址注册会议 https://dpregister.com/sreg/10188768/fc6df642e0。请注意，注册的参与者将在注册时收到他们的拨入号码。
可以在Journey Medical网站 “投资者” 部分的新闻和活动页面上访问网络直播， www.journeymedicalcorp.com，并且将在电话会议结束后的大约 30 天内继续可供重播。
关于卓越医疗公司
Journey Medical Corporation（纳斯达克股票代码：DERM）（“Journey Medical”）是一家商业阶段的制药公司，主要通过其高效的销售和营销模式，销售和营销经美国食品药品管理局批准的用于治疗皮肤病的处方药产品。该公司目前销售七种品牌和两种仿制产品，这些产品有助于治疗和治愈常见的皮肤病。Journey Medical团队由行业专家组成，他们在开发和商业化皮肤科一些最成功的处方品牌方面拥有丰富的经验。Journey Medical位于亚利桑那州斯科茨代尔，由丰泽生物技术公司（纳斯达克股票代码：FBIO）创立。Journey Medical的普通股根据经修订的1934年证券交易法注册，并定期向美国证券交易委员会（“SEC”）提交报告。有关 Journey Medical 的更多信息，请访问 www.journeymedicalcorp.com。
公司联系人：
Jaclyn Jaffe
卓越医疗公司
(781) 652-4500
ir@jmcderm.com
媒体关系联系人：
托尼·普洛霍罗斯
6 度
(908) 591-2839
tplohoros@6degreespr.com
资料来源：旅程医疗公司
2024 年 5 月 7 日发布
